Trials / Completed
CompletedNCT03563950
An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants
A Phase I, Open-Label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety and Tolerability of BMS-986224 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate if the blood levels of experimental medication BMS-986224 will be changed when given together with Rifampin, an antibiotic that affects specific enzymes involved with the breakdown of BMS-986224.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifampin | Specified dose on specified days |
| DRUG | BMS-986224 | Specified dose on specified days |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2018-07-27
- Completion
- 2018-07-27
- First posted
- 2018-06-20
- Last updated
- 2018-08-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03563950. Inclusion in this directory is not an endorsement.